A Cambridge, MA.-based firm got a $38 million boost towards it goal of harvesting animal organs to give to humans in dire need of a transplant. eGenesis, a spin-out from Harvard University, hopes to improve the supply of organs for patients that are stuck on the transplant waiting list.
While the seemingly science-fiction field of xenotransplantation is far away from bringing products into the clinic, it has grown in recent years thanks to the development of biological modification techniques like CRISPR-Cas9.
[Want to stay more on top of MDO content? Subscribe to our weekly e-newsletter.]